Timothy J. Yeatman

Dr. Timothy Yeatman

Timothy Joseph Yeatman, M.D. F.A.C.S. (born June 10, 1958) is the director of Gibbs Cancer Center and president of Gibbs Cancer Center & Research Institute in Spartanburg, South Carolina.[1] Yeatman held numerous positions at the Moffitt Cancer Center (MCC) in Florida over the past 20 years. Yeatman served as the associate center director for clinical investigations, the associate center director for translational research, the executive vice president for translational research, professor of surgery and oncologic sciences, and section head of hepatobiliary surgery at the Moffitt Cancer Center and the University of South Florida.[2] He was recently named chief scientific officer for the Center for Advancement of Science in Space (CASIS), a non-profit organization appointed by Congress and funded by NASA to oversee all scientific use of the International Space Station.[3]

Background

Yeatman was born in Cheverly, Maryland. He received his undergraduate degree at Duke University, where he graduated summa cum laude and Phi Beta Kappa. He received his medical degree from Emory University and completed his surgical internship and residency at the University of Florida, and then a surgical oncology fellowship at MD Anderson Cancer Center, prior to arriving at Moffitt Cancer Center.[4] He assumed his current role as director of Gibbs Cancer Center and president of Gibbs Cancer Center & Research Institute in October 2012 where he will develop a next generation cancer center focused on delivering personalized medicine and individualized cancer care.[5]

Career and research

Yeatman has been continuously funded by the National Cancer Institute (NCI) since 1997.[6] He spent 20 years at the Moffitt Cancer Center as a physician scientist, with a clinical and research focus on the problems linked to colorectal cancer. He has spent more than 10 years in the field of molecular profiling and gene expression classifier development, working in the environment of team science and multidisciplinary collaboration. Yeatman has active and completed grants funded by NCI as well as the state of Florida. Finally, he was recently awarded a UO1 SPECS2 grant to develop CRC predictive molecular signatures. He has helped deliver personalized cancer care by utilizing this large database to find the right patients for the right drug trials and matching patients through genetic analysis of cancers.[7] Yeatman holds numerous patents that include the identification of the first human mutations in the SRC oncogene (Patent Number 7803909)[8] and methods for matching patients to clinical trials using a molecular database (Patent Numbers 8175896, 8095389, 20110288890, 20080033658).[9][10]

Yeatman is a pioneer in personalized medicine, having headed the development of the world's largest human tumor bio-repository and database with comprehensive molecular profiling of approximately 20,000 tumor specimens. He was the principal architect of the Total Cancer Care (TCC) initiative in personalized medicine, and served as the president and founding chief scientific officer of M2Gen (a wholly owned subsidiary of the MCC that implemented and managed the TCC project).[11] He participated in recruiting a nationwide network of 18 hospitals (TCC Consortium) that collected, macrodissected, curated and profiled more than 20,000 snap frozen tumor samples on a single Affymetrix platform with a commercial pipeline. Yeatman also served as chair of the Joint Scientific Committee, and the co-chair of the Joint Operating Committee, which made him the primary liaison with Merck & Co. in developing and managing the more than $150 million project and the derivative science.[12]

Awards and recognition

Yeatman has received numerous honors and awards including the James IV Association of Surgeons Traveling Fellowship, Europe;[13] the Center Director’s Award for Outstanding Research at Moffitt Cancer Center;[14] and the James Ewing Foundation Trainee Award, Society of Surgical Oncology, and the Million Dollar Researcher award at the University of South Florida.[15] Yeatman has been continuously funded through additional grants from the American Cancer Society, including a Director’s Challenge Award for the global profiling of human colon cancer.[16] He is a member of numerous societies including the American Surgical Association and the Society of Surgical Oncology and the American Association for Cancer Research. He has published around 150 articles in the top peer-reviewed journals in his field,[17] including the prestigious Science,[18] Nature Genetics,[19] Nature Medicine,[20] Nature Reviews Cancer,[21] as well as the Journal of the National Cancer Institute,[22][23] and Cancer Research,.[24][25][26][27]

References

  1. ↑ http://www.gibbscancercenter.com/GibbsContentPage.aspx?nd=152
  2. ↑ 2. http://www.moffitt.org/research--clinical-trials/individual-researchers/timothy-joseph-yeatman-md
  3. ↑ http://www.iss-casis.org/NewsEvents/PressReleases/tabid/111/ArticleID/18/ArtMID/586/CASIS-Names-Dr-Timothy-J-Yeatman-Interim-Chief-Scientist.aspx
  4. ↑ http://www.moffitt.org/research--clinical-trials/individual-researchers/timothy-joseph-yeatman-md
  5. ↑ http://www.gibbscancercenter.com/GibbsContentPage.aspx?nd=172&news=82
  6. ↑ http://projectreporter.nih.gov/reporter_SearchResults.cfm?icde=17733415
  7. ↑ http://www.moffitt.org/research--clinical-trials/individual-researchers/timothy-joseph-yeatman-md
  8. ↑ http://www.patentfish.com/search.php
  9. ↑ http://www.patentfish.com/search.php
  10. ↑ http://patents.justia.com/inventor/timothy-yeatman
  11. ↑ http://www.bizjournals.com/tampabay/stories/2010/05/31/daily33.html
  12. ↑ http://www.bizjournals.com/tampabay/stories/2007/11/12/daily25.html
  13. ↑ http://jamesivassociationsurgeons.com/travelers-usa.php
  14. ↑ http://www.moffitt.org/research--clinical-trials/individual-researchers/timothy-joseph-yeatman-md
  15. ↑ http://investing.businessweek.com/research/stocks/private/person.asp?personId=108810183&privcapId=36398108&previousCapId=1340759&previousTitle=ONCOLYTICS%20BIOTECH%20INC
  16. ↑ http://www.moffitt.org/research--clinical-trials/individual-researchers/timothy-joseph-yeatman-md
  17. ↑ http://www.gibbscancercenter.com/media/file/yeatman-publications.pdf
  18. ↑ Attallah AM, Yeatman TJ, Noguchi PD, Johnson JB. Antibody-dependent cell-mediated cytotoxicity: detection by automated flow cytometry with ultramicro techniques. Science. 1980 Jul 18;209(4454):404-6. PMID 7384812.
  19. ↑ Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ. Activating SRC mutation in a subset of advanced human colon cancers. Nature Genetics. 1999 Feb;21(2):187-90. PMID 9988270.
  20. ↑ Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma, Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, Chang AC, Zhu CQ, Strumpf D, Hanash S, Shepherd FA, Ding K, Seymour L, Naoki K, Pennell N, Weir B, Verhaak R, Ladd-Acosta C, Golub T, Gruidl M, Sharma A, Szoke J, Zakowski M, Rusch V, Kris M, Viale A, Motoi N, Travis W, Conley B, Seshan VE, Meyerson M, Kuick R, Dobbin KK, Lively T, Jacobson JW, Beer DG. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nature Medicine. 2008 Aug;14(8):822-7. PMID 18641660.
  21. ↑ Yeatman TJ. A renaissance for SRC. Nature Reviews Cancer. 2004 Jun;4(6):470-80. Review. PMID 15170449.
  22. ↑ Chen DT, Hsu YL, Fulp WJ, Coppola D, Haura EB, Yeatman TJ, Cress WD. Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. Journal of the National Cancer Institute. 2011 Dec 21;103(24):1859-70. PMID 22157961.
  23. ↑ Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. Journal of the National Cancer Institute. 2002 Apr 3;94(7):513-21. PMID 11929952.
  24. ↑ Hegde P, Qi R, Gaspard R, Abernathy K, Dharap S, Earle-Hughes J, Gay C, Nwokekeh NU, Chen T, Saeed AI, Sharov V, Lee NH, Yeatman TJ, Quackenbush J. Identification of tumor markers in models of human colorectal cancer using a 19,200-element complementary DNA microarray. Cancer Research. 2001 Nov 1;61(21):7792-7. PMID 11691794.
  25. ↑ Irby RB, Yeatman TJ. Increased Src activity disrupts cadherin/catenin-mediated homotypic adhesion in human colon cancer and transformed rodent cells. Cancer Research. 2002 May 1;62(9):2669-74. PMID 11980666.
  26. ↑ Chen T, Yang I, Irby R, Shain KH, Wang HG, Quackenbush J, Coppola D, Cheng JQ, Yeatman TJ. Regulation of caspase expression and apoptosis by adenomatous polyposis coli. Cancer Research. 2003 Aug 1;63(15):4368-74. PMID 12907606.
  27. ↑ Irby RB, Malek RL, Bloom G, Tsai J, Letwin N, Frank BC, Verratti K, Yeatman TJ, Lee NH. Iterative microarray and RNA interference-based interrogation of the SRC-induced invasive phenotype. Cancer Research. 2005 Mar 1;65(5):1814-21. PMID 15753379.
This article is issued from Wikipedia - version of the 3/8/2014. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.